Find a Tender · Contract
NHS National Framework for Natalizumab
A public procurement published by NHS England via Find a Tender.
- —
- Award value
- £175m
- Tender value
- 2
- Suppliers
- 2
- Awards
- 2
- Notices
- Contract
- Stage
Overview
NHS National Framework for Natalizumab - February 2024 <br/>Offer reference number: CM/PHR/23/5701 <br/>Period of framework: 1 February 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
Key details
- Buyer
- NHS England
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- active
- CPV classification
- 33600000 — Pharmaceutical products
- Currency
- GBP
- Total award value
- —
- Tender value
- £175,000,000
- First published
- 2 Nov 2023
- Last updated
- 2 Feb 2024
Awards
2 awards recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| Sandoz Ltd | 01547204 | — | active | — |
| Biogen | 06151086 | — | active | — |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
More from NHS England
FAQs about this procurement
Who is the buyer for "NHS National Framework for Natalizumab"?
NHS National Framework for Natalizumab is a UK public-sector procurement published by NHS England via Find a Tender.
Has "NHS National Framework for Natalizumab" been awarded?
Yes — 2 awards are recorded, with a reported total value of £175,000,000. The current lifecycle stage is "Contract".
Which suppliers are involved in "NHS National Framework for Natalizumab"?
2 suppliers are linked: Sandoz Ltd, Biogen.
What is "NHS National Framework for Natalizumab" worth?
The reported tender value is £175,000,000.
When was "NHS National Framework for Natalizumab" published?
It was first published on 2 Nov 2023 and last updated on 2 Feb 2024, across 2 notices.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable